Physician profile
Sarfaraz Memon
NPI 1962727982
$30,473.30
in general payments reported to CMS, 2019-2025
20 companies · $3,307 in 2025
The $3,307 reported for 2025 was more than what 77% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $177 · 2021: $522 · 2022: $23K · 2023: $2,634 · 2024: $1,012 · 2025: $3,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,598 · Travel and Lodging: $2,354 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,598.40 |
| Travel and Lodging | $2,353.73 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $26,691.05 | 2021-2025 | Corevalve Evolut R, Apollotm, Symplicity G3 |
| Edwards Lifesciences Corporation | $2,126.81 | 2022-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Shockwave Medical, INC | $315.81 | 2022-2025 | |
| Astellas Pharma US INC | $251.99 | 2019-2021 | |
| Cardiovascular Systems INC. | $229.49 | 2021-2022 | |
| Abbott Laboratories | $193.51 | 2021-2024 | Absolute Pro, Amplatzer Amulet |
| Boston Scientific Corporation | $115.46 | 2019-2023 | Avvigo Guidance System |
| Astrazeneca Pharmaceuticals LP | $101.07 | 2020-2022 | |
| Bard Peripheral Vascular, INC. | $76.41 | 2025 | Fluency Endovascular Stent Graft |
| E.R. Squibb & Sons, L.L.C. | $69.53 | 2019-2020 | |
| Amgen INC. | $51.52 | 2020-2022 | |
| Inari Medical, INC. | $46.52 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Chiesi USA, INC. | $43.02 | 2023-2024 | Kengreal |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $39.62 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $34.52 | 2019-2023 | Xarelto |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $22.17 | 2019 | |
| Penumbra, INC. | $20.25 | 2023 | Indigo System |
| Lantheus Medical Imaging, INC. | $16.46 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.09 | 2019 | |
| Opsens INC. | $13.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarfaraz Memon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.